CL2019000909A1 - Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. - Google Patents

Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a.

Info

Publication number
CL2019000909A1
CL2019000909A1 CL2019000909A CL2019000909A CL2019000909A1 CL 2019000909 A1 CL2019000909 A1 CL 2019000909A1 CL 2019000909 A CL2019000909 A CL 2019000909A CL 2019000909 A CL2019000909 A CL 2019000909A CL 2019000909 A1 CL2019000909 A1 CL 2019000909A1
Authority
CL
Chile
Prior art keywords
methods
human subject
subject suffering
reduce proteinuria
immunoglobulin nephropathy
Prior art date
Application number
CL2019000909A
Other languages
English (en)
Inventor
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Nigel John Brunskill
Tom Dudler
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of CL2019000909A1 publication Critical patent/CL2019000909A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

EN UN ASPECTO, LA INVENCIÓN PROPORCIONA MÉTODOS PARA REDUCIR LA PROTEINURIA EN UN SUJETO HUMANO QUE PADECE, O ESTÁ EN RIESGO DE DESARROLLAR NEFROPATÍA POR INMUNOGLOBULINA A (IGAN); LOS MÉTODOS COMPRENDEN LA ETAPA DE ADMINISTRAR, A UN SUJETO QUE LO NECESITA, UNA CANTIDAD DE UN ANTICUERPO INHIBIDOR DE MASP-2 EFICAZ PARA INHIBIR LA ACTIVACIÓN DEL COMPLEMENTO MASP-2- DEPENDIENTE.
CL2019000909A 2016-10-13 2019-04-04 Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. CL2019000909A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30

Publications (1)

Publication Number Publication Date
CL2019000909A1 true CL2019000909A1 (es) 2019-06-14

Family

ID=61906454

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019000909A CL2019000909A1 (es) 2016-10-13 2019-04-04 Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a.
CL2019003485A CL2019003485A1 (es) 2016-10-13 2019-11-28 Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2019003485A CL2019003485A1 (es) 2016-10-13 2019-11-28 Métodos para redicur la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a. (divisional solicitud 201900909)

Country Status (18)

Country Link
EP (1) EP3525798A4 (es)
JP (1) JP6893554B2 (es)
KR (1) KR102348939B1 (es)
CN (2) CN110177557A (es)
AU (1) AU2017342428B2 (es)
BR (1) BR112019007426A2 (es)
CA (2) CA3039927C (es)
CL (2) CL2019000909A1 (es)
GE (1) GEP20247587B (es)
IL (1) IL265981A (es)
JO (1) JOP20190068A1 (es)
MA (1) MA46541A (es)
MX (1) MX2019004074A (es)
PH (1) PH12019500711A1 (es)
SG (1) SG11201902941UA (es)
UA (1) UA126908C2 (es)
WO (1) WO2018071701A1 (es)
ZA (1) ZA201902933B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374819B1 (en) * 2003-05-12 2017-03-22 Helion Biotech ApS Antibodies to MASP-2
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
ES2617920T3 (es) * 2009-10-16 2017-06-20 Omeros Corporation Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
WO2012100262A1 (en) * 2011-01-21 2012-07-26 Fibrogen, Inc. Therapeutic method using anti - ctgf antibody
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
KR101641057B1 (ko) * 2011-05-04 2016-07-20 오메로스 코포레이션 Masp-2 의존적 보체 활성화를 억제하는 조성물
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
MX2016005017A (es) * 2013-10-17 2016-11-07 Omeros Corp Metodos para el tratamiento de condiciones asociadas con la activacion del complemento dependiente de masp-2.
IL294411A (en) * 2016-01-05 2022-08-01 Omeros Corp masp-2 suppressors for use in suppressing fibrosis
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
BR112019007426A2 (pt) 2019-07-02
CN116726163A (zh) 2023-09-12
NZ753260A (en) 2021-11-26
CN110177557A (zh) 2019-08-27
CA3039927A1 (en) 2018-04-19
EP3525798A4 (en) 2020-07-08
AU2017342428B2 (en) 2021-02-04
AU2017342428A1 (en) 2019-05-23
CL2019003485A1 (es) 2020-04-13
JP2019534271A (ja) 2019-11-28
EP3525798A1 (en) 2019-08-21
ZA201902933B (en) 2023-05-31
MX2019004074A (es) 2019-06-10
PH12019500711A1 (en) 2019-11-18
KR102348939B1 (ko) 2022-01-12
JP6893554B2 (ja) 2021-06-23
IL265981A (en) 2019-06-30
MA46541A (fr) 2019-08-21
WO2018071701A1 (en) 2018-04-19
JOP20190068A1 (ar) 2019-04-01
CA3039927C (en) 2023-10-10
UA126908C2 (uk) 2023-02-22
CA3210384A1 (en) 2018-04-19
SG11201902941UA (en) 2019-05-30
KR20190063475A (ko) 2019-06-07
GEP20247587B (en) 2024-01-25

Similar Documents

Publication Publication Date Title
CL2018001817A1 (es) Métodos para la inhibición de la fibrosis en un sujeto en necesidad de ellos
CL2017000558A1 (es) Terapia de combinación
CY1122804T1 (el) Μονοκλωνικα αντισωματα εναντι ανθρωπινου αντιγονου ωριμανσης β κυτταρων (βcμα)
CO2021001893A2 (es) Anticuerpos anti-gdf15, composiciones y métodos de uso
ECSP17070399A (es) Anticuerpos contra icos
CL2017001924A1 (es) Anticuerpos anti-transtiretina
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
EA201790569A1 (ru) Антитела и иммуноконъюгаты против cll-1
CO2017003490A2 (es) Moléculas de anticuerpos a pd-l1
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CR20160257A (es) Anticuerpos e inmunoconjugados anti-cd33
CU24498B1 (es) Anticuerpos de factor xi
CL2019000909A1 (es) Métodos para reducir la proteinuria en un sujeto humano que padece de nefropatía por inmunoglobulina a.
CL2017003255A1 (es) Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin.
CR20160500A (es) Anticuerpos anti-ox40 y métodos de uso
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
CL2016001979A1 (es) Métodos de tratamiento de enfermedad de alzheimer.
CU24427B1 (es) Moléculas de anticuerpo que se unen a tim-3
CO2017008482A2 (es) Anticuerpos anti-transtiretina
CO2017008469A2 (es) Anticuerpos anti-transtiretina
CO2018012987A2 (es) Anticuerpos que reconocen tau
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CL2019000799A1 (es) Anticuerpos y fragmentos de los mismos que se unen al receptor cannabinoide 1 (cb1) humano. (divisional solicitud 201602433)
CL2018003349A1 (es) Combinación de anticuerpo anti-cd20, inhibidor selectivo de pelasa de p13, e inhibidor de btk para tratar trastornos proliferativos de células b.